

WHAT IS CLAIMED IS:

1. An isolated and/or recombinant monoclonal antibody or an antibody fragment thereof, wherein the antibody or antibody fragment is a 4N12, 2B4, 2H1, 3E23, 3N23, 4J14, 4J21, 5M16, 5O14, 8G18, 1I9, 1L1, 1M9, 1O5, 1O6, 2A2, 2C2, 2D12, 3A2, 3B4, 3E23, 3H5, 3I21, 3K11, 4B8, 4B10, 9D14 or 9A11 antibody or antibody fragment thereof comprising clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
2. The monoclonal antibody or an antibody fragment thereof of claim 1, wherein said 4N12, 2B4, 2H1, 3E23, 3N23, 4J14, 4J21, 5M16, 5O14, 8G18, 1I9, 1L1, 1M9, 1O5, 1O6, 2A2, 2C2, 2D12, 3A2, 3B4, 3E23, 3H5, 3I21, 3K11, 4B8, 4B10, 9D14 or 9A11 antibody or antibody fragment is encoded by light and heavy chain variable sequences according to clone-paired sequences from Table 1.
3. The monoclonal antibody or an antibody fragment thereof of claim 1, wherein said 4N12, 2B4, 2H1, 3E23, 3N23, 4J14, 4J21, 5M16, 5O14, 8G18, 1I9, 1L1, 1M9, 1O5, 1O6, 2A2, 2C2, 2D12, 3A2, 3B4, 3E23, 3H5, 3I21, 3K11, 4B8, 4B10, 9D14 or 9A11 antibody or antibody fragment is encoded by light and heavy chain variable sequences having at least 70%, 80%, or 90% identity to clone-paired sequences from Table 1.
4. The monoclonal antibody or an antibody fragment thereof of claim 1, wherein said 4N12, 2B4, 2H1, 3E23, 3N23, 4J14, 4J21, 5M16, 5O14, 8G18, 1I9, 1L1, 1M9, 1O5, 1O6, 2A2, 2C2, 2D12, 3A2, 3B4, 3E23, 3H5, 3I21, 3K11, 4B8, 4B10, 9D14 or 9A11 antibody or antibody fragment is encoded by light and heavy chain variable sequences having at least 95% identity to clone-paired sequences from Table 1.
5. The monoclonal antibody or an antibody fragment thereof of claim 1, wherein said 4N12, 2B4, 2H1, 3E23, 3N23, 4J14, 4J21, 5M16, 5O14, 8G18, 1I9, 1L1, 1M9, 1O5, 1O6, 2A2, 2C2, 2D12, 3A2, 3B4, 3E23, 3H5, 3I21, 3K11, 4B8, 4B10, 9D14 or 9A11 antibody or antibody fragment comprises light and heavy chain variable sequences according to clone-paired sequences from Table 2.
6. The monoclonal antibody or an antibody fragment thereof of claim 1, wherein said 4N12, 2B4, 2H1, 3E23, 3N23, 4J14, 4J21, 5M16, 5O14, 8G18, 1I9, 1L1, 1M9, 1O5, 1O6, 2A2, 2C2, 2D12, 3A2, 3B4, 3E23, 3H5, 3I21, 3K11, 4B8, 4B10, 9D14 or 9A11 antibody or antibody fragment comprises light and heavy chain variable sequences having 95% identity to clone-paired sequences from Table 2.
7. The monoclonal antibody or an antibody fragment thereof of claim 1, wherein the antibody fragment is a recombinant ScFv (single chain fragment variable) antibody, Fab fragment, F(ab')₂ fragment, or Fv fragment.

8. The monoclonal antibody or an antibody fragment thereof of claim 1, wherein said antibody is a chimeric antibody, or is bispecific antibody that targets a Chikungunya virus antigen other than glycoprotein.
9. The monoclonal antibody or an antibody fragment thereof of claim 1, wherein said antibody is an IgG.
10. The monoclonal antibody or an antibody fragment thereof of claim 1, wherein said antibody or antibody fragment further comprises a cell penetrating peptide and/or is an intrabody.
11. A hybridoma encoding an antibody or antibody fragment thereof according to any one of claims 1-10.
12. A method of detecting a Chikungunya virus infection in a subject comprising:
 - (a) contacting a sample from said subject with an antibody or antibody fragment thereof of any one of claims 1-10; and
 - (b) detecting Chikungunya virus glycoprotein E2 in said sample by binding of said antibody or antibody fragment thereof to E2 in said sample.
13. The method of claim 12, wherein said sample is a body fluid.
14. The method of claim 12, further comprising performing steps (a) and (b) a second time and determining a change in the E2 levels as compared to the first assay.
15. Use of an antibody or antibody fragment thereof according to any one of claims 1-10 or an RNA or DNA sequence or vector encoding the antibody or antibody fragment thereof according to any one of claims 1-10 in the manufacture of a medicament for treating a subject infected with Chikungunya virus, or reducing the likelihood of infection of a subject at risk of contracting Chikungunya virus.
16. The use of claim 15, wherein said medicament is to be administered prior to infection.
17. The use of claim 15, wherein said medicament is to be administered after infection.

18. A pharmaceutical composition comprising the isolated and/or recombinant monoclonal antibody or antibody fragment thereof according to any one of claims 1-10.
19. A cell line producing the isolated and/or recombinant monoclonal antibody or antibody fragment thereof according to any one of claims 1-10.
20. A method of producing the isolated and/or recombinant monoclonal antibody or antibody fragment thereof according to any one of claims 1-10 wherein said method comprises the step of:
 - (a) culturing a cell line producing said isolated and/or recombinant monoclonal antibody or antibody fragment thereof;
 - (b) purifying the produced isolated and/or recombinant monoclonal antibody or antibody fragment thereof; and optionally
 - (c) formulating said isolated and/or recombinant monoclonal antibody or antibody fragment thereof into a pharmaceutical composition.
21. An isolated and/or recombinant monoclonal antibody, wherein the antibody or antibody fragment thereof is obtainable by the method of claim 20.
22. A kit comprising one isolated and/or recombinant monoclonal antibody or antibody fragment thereof according to any one of claims 1-10 and optionally packaging material.